Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.03T
24h Vol:
$10.99B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo  IMRX
Immuneering Corporation
IMRX
58 / 100
Penny Stock
$1.45arrow_drop_up0.69%$0.01

Performance History

Chart placeholder
Key Stats
Open$1.55
Prev. Close$1.55
EPS-1.86
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap43590500.00
PE Ratio-
LOWHIGH
Day Range1.41
1.55
52 Week Range1.38
11.92
Ratios
P/B Ratio0.60
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %-5.86%
EBITDA Margin %-
ROE %-61.38%
EPS-1.86

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$808.45
24H (%)arrow_drop_up0.69%
24H ($)$5.54
MARKET CAP$744.33B
PRICE$516.83
24H (%)arrow_drop_down0.86%
24H ($)-$4.51
MARKET CAP$476.05B
PRICE$149.70
24H (%)arrow_drop_down2.47%
24H ($)-$3.80
MARKET CAP$364.05B
PRICE$131.09
24H (%)0.00%
24H ($)-$0.01
MARKET CAP$332.27B

About Immuneering Corporation (IMRX)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D.
Headquarters
Cambridge
Employees
66
Exchange
NASDAQ
add Immuneering Corporation to watchlist

Keep an eye on Immuneering Corporation

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Immuneering Corporation's (IMRX) price per share?

The current price per share for Immuneering Corporation (IMRX) is $1.42. The stock has seen a price change of -$0.13 recently, indicating a -8.39% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Immuneering Corporation (IMRX)?

For Immuneering Corporation (IMRX), the 52-week high is $11.92, which is 739.44% from the current price. The 52-week low is $1.38, the current price is 2.9% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Immuneering Corporation (IMRX) a growth stock?

Immuneering Corporation (IMRX) has shown an average price growth of 0.41% over the past three years. It has received a score of 42 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Immuneering Corporation as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Immuneering Corporation (IMRX) stock price performance year to date (YTD)?

As of the latest data, Immuneering Corporation (IMRX) has a year-to-date price change of -80.6%. Over the past month, the stock has experienced a price change of -3.4%. Over the last three months, the change has been -77.78%. Over the past six months, the figure is -82%.

help
Is Immuneering Corporation (IMRX) a profitable company?

Immuneering Corporation (IMRX) has a net income of -$53.47M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$58.41M. Furthermore, the EBITDA is -$58.69M.

help
What is the market capitalization of Immuneering Corporation (IMRX)?

Immuneering Corporation (IMRX) has a market capitalization of $43.59M. The average daily trading volume is 164.6K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level